Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.02
-0.7%
$5.64
$2.81
$485.37
$2.30M5.58610,023 shs130,195 shs
Ceapro Inc. stock logo
CRPOF
Ceapro
$0.17
$0.17
$0.11
$0.40
$13.31M1.4715,466 shsN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$3.22
-2.1%
$3.24
$3.04
$18.00
$4.35M0.73105,261 shs4,700 shs
Medicure Inc. stock logo
MCUJF
Medicure
$0.91
$0.76
$0.44
$0.94
$9.51M1.06220 shsN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$7.58
+2.3%
$10.50
$0.29
$3.72
$321.92M3.931.22 million shs1.86 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
0.00%-1.95%-36.82%-89.87%-99.96%
Ceapro Inc. stock logo
CRPOF
Ceapro
0.00%0.00%0.00%0.00%0.00%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
0.00%0.00%0.00%0.00%-67.36%
Medicure Inc. stock logo
MCUJF
Medicure
0.00%0.00%+5.61%+88.42%+1.27%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.00%+6.76%+34.40%+42.21%-8.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
2.1154 of 5 stars
3.53.00.00.00.60.01.3
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Medicure Inc. stock logo
MCUJF
Medicure
N/AN/AN/AN/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
3.00
Buy$219,040.007,252,880.13% Upside
Ceapro Inc. stock logo
CRPOF
Ceapro
0.00
N/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
0.00
N/AN/AN/A
Medicure Inc. stock logo
MCUJF
Medicure
0.00
N/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.11M0.74N/AN/A$65.21 per share0.05
Ceapro Inc. stock logo
CRPOF
Ceapro
$7.14M1.86$0.06 per share2.74$0.32 per share0.53
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.35$0.14 per share23.15$6.39 per share0.50
Medicure Inc. stock logo
MCUJF
Medicure
$15.99M0.60$0.09 per share10.22$1.45 per share0.63
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$22.50M14.31N/AN/A$1.04 per share7.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)
Ceapro Inc. stock logo
CRPOF
Ceapro
-$3.49M-$0.06N/AN/A-69.60%-20.30%-18.07%N/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$4.870.66N/A22.79%-73.69%-48.17%N/A
Medicure Inc. stock logo
MCUJF
Medicure
-$760K-$0.13N/AN/A-8.15%-8.74%-6.05%8/12/2025 (Estimated)
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/A

Latest APVO, CRPOF, MCUJF, GHSI, and UMRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Medicure Inc. stock logo
MCUJF
Medicure
N/A-$0.05N/A-$0.05N/A$3.82 million
5/15/2025Q1 2025
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$84.20-$87.80-$3.60-$4.39N/AN/A
4/25/2025Q4 2024
Medicure Inc. stock logo
MCUJF
Medicure
N/A-$0.04N/A-$0.04N/A$4.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/AN/A
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$5.00155.28%N/A102.67%N/A
Medicure Inc. stock logo
MCUJF
Medicure
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/A
0.67
0.67
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
11.00
7.72
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
16.68
16.59
Medicure Inc. stock logo
MCUJF
Medicure
0.02
1.71
1.29
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.18
2.90
2.90

Institutional Ownership

CompanyInstitutional Ownership
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
8.06%
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
20.21%
Medicure Inc. stock logo
MCUJF
Medicure
N/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
26.39%

Insider Ownership

CompanyInsider Ownership
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
0.01%
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
1.32%
Medicure Inc. stock logo
MCUJF
Medicure
12.90%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
31.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
50760,000756,000Not Optionable
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A78.29 millionN/ANot Optionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
101.35 million1.33 millionNot Optionable
Medicure Inc. stock logo
MCUJF
Medicure
N/A10.44 million9.09 millionNot Optionable
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
7242.47 millionN/ANot Optionable

Recent News About These Companies

Cogent Biosciences (COGT) Initiated with a Buy at Scotiabank
Cogent Biosciences initiated with an Outperform at Scotiabank
Cogent Biosciences reports Q4 net loss $67.9M vs. $54.4M last year
Cogent Biosciences sees cash runway into late 2026
Cogent Biosciences exec buys $332K in common stock
Piper Sandler Sticks to Its Buy Rating for Cogent Biosciences (COGT)
Cogent Biosciences price target lowered to $14 from $17 at H.C. Wainwright
Cogent Biosciences (COGT) Gets a Buy from J.P. Morgan
Cogent Biosciences price target raised to $21 from $19 at JPMorgan

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aptevo Therapeutics stock logo

Aptevo Therapeutics NASDAQ:APVO

$3.02 -0.02 (-0.66%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$3.02 +0.00 (+0.03%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Ceapro stock logo

Ceapro OTCMKTS:CRPOF

$0.17 0.00 (0.00%)
As of 06/6/2024

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

Guardion Health Sciences stock logo

Guardion Health Sciences NASDAQ:GHSI

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Medicure stock logo

Medicure OTCMKTS:MCUJF

$0.91 0.00 (0.00%)
As of 07/3/2025

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.